Literature DB >> 31364692

Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Nicole Salazar-Austin, David W Dowdy, Richard E Chaisson, Jonathan E Golub.   

Abstract

Tuberculosis (TB) has been a leading infectious cause of death worldwide for much of human history, with 1.6 million deaths estimated in 2017. The Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health has played an important role in understanding and responding to TB, and it has made particularly substantial contributions to prevention of TB with chemoprophylaxis. TB preventive therapy is highly efficacious in the prevention of TB disease, yet it remains underutilized by TB programs worldwide despite strong evidence to support its use in high-risk groups, such as people living with HIV and household contacts, including those under 5 years of age. We review the evidence for TB preventive therapy and discuss the future of TB prevention.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  TB preventive therapy (TPT); prevention; tuberculosis

Mesh：

Year:  2019        PMID： 31364692      PMCID： PMC7212403          DOI： 10.1093/aje/kwz172

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


  78 in total

Review 1.  How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

Authors:  G W Comstock
Journal:  Int J Tuberc Lung Dis       Date:  1999-10       Impact factor: 2.373

2.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

3.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Authors:  Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson
Journal:  Clin Infect Dis       Date:  2014-11-02       Impact factor: 9.079

4.  Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report.

Authors:  S FEREBEE; F W MOUNT; A ANASTASIADES
Journal:  Am Rev Tuberc       Date:  1957-12

5.  New regimens to prevent tuberculosis in adults with HIV infection.

Authors:  Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.

Authors:  C C Whalen; J L Johnson; A Okwera; D L Hom; R Huebner; P Mugyenyi; R D Mugerwa; J J Ellner
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

7.  Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.

Authors:  Suzanne Verver; Robin M Warren; Nulda Beyers; Madalene Richardson; Gian D van der Spuy; Martien W Borgdorff; Donald A Enarson; Marcel A Behr; Paul D van Helden
Journal:  Am J Respir Crit Care Med       Date:  2005-04-14       Impact factor: 21.405

8.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

Authors:  N A Halsey; J S Coberly; J Desormeaux; P Losikoff; J Atkinson; L H Moulton; M Contave; M Johnson; H Davis; L Geiter; E Johnson; R Huebner; R Boulos; R E Chaisson
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

9.  Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents.

Authors:  K H Hsu
Journal:  JAMA       Date:  1984-03-09       Impact factor: 56.272

10.  Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey.

Authors:  Hae-Young Kim; David W Dowdy; Neil A Martinson; Jonathan E Golub; John F P Bridges; Colleen F Hanrahan
Journal:  J Int AIDS Soc       Date:  2018-07       Impact factor: 5.396
View more
  3 in total

1.  A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.

Authors:  Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

2.  Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.

Authors:  Andrew Kazibwe; Bonniface Oryokot; Levicatus Mugenyi; David Kagimu; Abraham Ignatius Oluka; Darlius Kato; Simple Ouma; Edmund Tayebwakushaba; Charles Odoi; Kizito Kakumba; Ronald Opito; Ceasar Godfrey Mafabi; Michael Ochwo; Robert Nkabala; Wilber Tusiimire; Agnes Kateeba Tusiime; Sarah Barbara Alinga; Yunus Miya; Michael Bernard Etukoit; Irene Andia Biraro; Bruce Kirenga
Journal:  PLoS One       Date:  2022-05-16       Impact factor: 3.752

3.  The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there.

Authors:  C Lange; A Kay; A M Mandalakas
Journal:  Int J Tuberc Lung Dis       Date:  2022-02-01       Impact factor: 3.427
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.